Evidence map›Paper›PMID 37212148›Full record

ArticleCirculation. Heart failure2023

Long-Term Outcomes of Early Coronary Artery Disease Testing After New-Onset Heart Failure.

Jimmy Zheng, Paul A Heidenreich, Shun Kohsaka, William F Fearon, Alexander T Sandhu

Open access · bronzeAbstract read
In one paragraph

Article in Circulation. Heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Jimmy ZhengStanford University School of Medicine, CA (J.Z.).ORCID 0000-0002-2009-2059
Paul A HeidenreichDivision of Cardiovascular Medicine, Department of Medicine, Stanford University, CA (P.A.H., W.F.F., A.T.S.).ORCID 0000-0001-7730-8490
Shun KohsakaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (S.K.).ORCID 0000-0003-3779-2972
William F FearonDivision of Cardiovascular Medicine, Department of Medicine, Stanford University, CA (P.A.H., W.F.F., A.T.S.).ORCID 0000-0003-1799-1368
Alexander T SandhuDivision of Cardiovascular Medicine, Department of Medicine, Stanford University, CA (P.A.H., W.F.F., A.T.S.).ORCID 0000-0003-3208-1143
Twitter (United States) · USDepartment of Veterans Affairs · AUKeio University · JPStanford University · US

Funding

Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
The Effect of Value-based Payment on Heart Failure Quality of Care (Value-HF)K23HL151672 · NHLBI · STANFORD UNIVERSITY · PI SANDHU, ALEXANDER · 2020 to 2024
$854k
NCATS NIH HHS UL1 TR001085NHLBI NIH HHS K23 HL151672
6 · The paper itself

Abstract

backgroundCoronary artery disease (CAD) testing remains underutilized in patients with newly diagnosed heart failure (HF). The longitudinal clinical impact of early CAD testing has not been well-characterized. We investigated changes in clinical management and long-term outcomes after early CAD evaluation in patients with incident HF.

methodsWe identified Medicare patients with incident HF from 2006 to 2018. The exposure variable was early CAD testing within 1 month of initial HF diagnosis. Covariate-adjusted rates of cardiovascular interventions after testing, including CAD-related management, were modeled using mixed-effects regression with clinician as a random intercept. We assessed mortality and hospitalization outcomes using landmark analyses with inverse probability-weighted Cox proportional hazards models. Falsification end points and mediation analysis were employed for bias assessment.

resultsAmong 309 559 patients with new-onset HF without prior CAD, 15.7% underwent early CAD testing. Patients who underwent prompt CAD evaluation had higher adjusted rates of subsequent antiplatelet/statin prescriptions and revascularization, guideline-directed therapy for HF, and stroke prophylaxis for atrial fibrillation/flutter than controls. In weighted Cox models, 1-month CAD testing was associated with significantly reduced all-cause mortality (hazard ratio, 0.93 [95% CI, 0.91-0.96]). Mediation analyses indicated that ≈70% of this association was explained by CAD management, largely from new statin prescriptions. Falsification end points (outpatient diagnoses of urinary tract infection and hospitalizations for hip/vertebral fracture) were nonsignificant.

conclusionsEarly CAD testing after incident HF was associated with a modest mortality benefit, driven mostly by subsequent statin therapy. Further investigation on clinician barriers to testing and treating high-risk patients may improve adherence to guideline-recommended cardiovascular interventions.

Indexed as

Atrial FibrillationCoronary Artery DiseaseHeart FailureHydroxymethylglutaryl-CoA Reductase InhibitorsAgedHumansMedicareUnited StatesHydroxymethylglutaryl-CoA Reductase Inhibitorscoronary artery diseasedelayed diagnosisearly medical interventionheart failureMedicaremortality

Identifiers

PMID37212148
PMCPMC10523905
OpenAlexW4377221360

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.